SCHEMBL4286199

SCHEMBL4286199

Cc1ccc(S(=O)(=O)/N=c2\ccc(Oc3cccc([N+](=O)[O-])c3)cn2CC(N)=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
LPAR3 Q9UBY5 1/20 0.43
KMT2A Q03164 4/20 0.42
GPR17 Q13304 1/20 0.41
F2 P00734 2/20 0.41
PRSS1 P07477 2/20 0.41
PRSS2 P07478 2/20 0.41
PRSS3 P35030 2/20 0.41
MAPT P10636 4/20 0.41
ALDH1A1 P00352 4/20 0.41
LMNA P02545 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
PGR P06401 1/20 0.40
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 2/20 0.38
MAPK1 P28482 1/20 0.38
POLB P06746 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636094 1.00 CYP2C9 (0.46) CYP2C9CYP2C19LPAR3KMT2AGPR17
SCHEMBL4286202 1.00 CYP2C9 (0.46) CYP2C9CYP2C19LPAR3KMT2AGPR17
SCHEMBL13639015 0.85 HTT (0.38) CYP2C9CYP2C19KMT2AF2PRSS1
SCHEMBL14949662 0.79 POLB (0.49) KMT2AF2PRSS1PRSS2PRSS3
SCHEMBL4312914 0.79 POLB (0.49) KMT2AF2PRSS1PRSS2PRSS3
SCHEMBL4284151 0.78 POLB (0.37) CYP2C9CYP2C19KMT2AMAPTLMNA
SCHEMBL4284146 0.78 POLB (0.37) CYP2C9CYP2C19KMT2AMAPTLMNA
SCHEMBL14949660 0.78 POLB (0.39) CYP2C9CYP2C19KMT2AMAPTMEN1
SCHEMBL14949661 0.78 POLB (0.39) CYP2C9CYP2C19KMT2AMAPTMEN1
SCHEMBL13498732 0.77 POLB (0.47) CYP2C9KMT2AF2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX CYP2C9 1211/4885CYP2C19 1345/4885LPAR3 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.